Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

RECRUITING

Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).

Lead Sponsor:

Tianjin Institute of Pharmaceutical Research Co., Ltd

Conditions:

Ischemic Stroke

Eligibility:

All Genders

40+ years

Phase:

PHASE2

Brief Summary

This study is designed to evaluate efficacy and safety of tiprogrel in the treatment of patients with acute ischemic cerebrovascular events.

Detailed Description

To evaluate the safety and efficacy of Tiprogrel at different doses within 24 hours after symptom onset in Patients with Acute Minor Ischaemic Stroke or High-risk Transient Ischaemic Attack. Patients ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Age ≥ 40 years
  • Acute Minor Ischaemic Stroke：AIS is defined as acute onset of neurological deficit attributed to focal brain ischaemia, NIHSS ≤5, and either of the following imaging characteristics:
  • Acute single infarction with ≥50% stenosis of a major intracranial or extracranial artery.
  • Acute multiple infarctions attributed to large-artery atherosclerosis, including non-stenotic vulnerable plaques.
  • TIA with high risk of stroke: ABCD2 score ≥ 6 at the time of randomization, and the following imaging characteristic:
  • a）TIA with ≥50% stenosis of a major intracranial or extracranial artery. 3）Can be treated with study drug within 24 hours of symptoms onset\*(\*Symptom onset is defined by the "last seen normal" principle) 4）A man or woman of childbearing potential does not have any plan to have a child from signing the informed consent to 3 months after the last dose 5）Written informed consent Exclusion Criteria
  • Bleeding or other pathological brain disorders including malformation, tumor, abscess or other major non-ischemic brain disease on baseline head CT or MRI
  • Isolated or pure sensory symptoms, isolated visual changes, or isolated dizziness/vertigo without evidence of acute infarction on baseline head CT or MRI.
  • Preceding mRS\> 2
  • Contraindication to anti-platelet therapy
  • Clear indication for anticoagulation
  • Two or more antiplatelet drugs have been used continuously for ≥3 days before enrollment.
  • Used heparin or oral anticoagulant drugs within 10 days before enrollment
  • Undergone intravenous or arterial thrombolysis and mechanical thrombectomy within 24 hours before enrollment
  • History of intracranial hemorrhage or amyloid angiopathy
  • History of aneurysm
  • Diagnosis or suspicious diagnosis of acute coronary syndrome
  • History of asthma
  • High-risk for bradyarrhythmia
  • Anticipated requirement for long-term (\>5 days) non-steroidal anti-inflammatory drugs or NSAIDs within the 8th day of randomization
  • History of gastrointestinal bleeding within 3 months before enrollment or major surgery within 30 days
  • Iatrogenic causes of minor stroke or TIA
  • Planned or likely revascularization within the next 3 months, scheduled for surgery or interventional treatment requiring study drug cessation
  • Severe non-cardiovascular comorbidity with life expectancy \< 3 months
  • Women of childbearing age who have not taken effective contraceptive measures and have a positive pregnancy test record, as well as women who are pregnant or breastfeeding
  • Currently receiving an experimental drug or device
  • Participation in another clinical study with an experimental product during the last 30 days
  • Inability to understand and/or follow research procedures due to mental, cognitive, or emotional disorders
  • Hemoglobin \<90g/L %
  • Permanent hypertension
  • Subjects who were judged by the investigator to be unsuitable for this clinical study

Exclusion

    Key Trial Info

    Start Date :

    February 21 2025

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    June 1 2026

    Estimated Enrollment :

    600 Patients enrolled

    Trial Details

    Trial ID

    NCT06601127

    Start Date

    February 21 2025

    End Date

    June 1 2026

    Last Update

    March 7 2025

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Central Hospital Affiliated to Shenyang Medical College

    Shenyang, Liaoning, China

    2

    Beijing Tiantan Hosptial, Capital Medical University

    Beijing, China